COMMUNIQUÉS West-GlobeNewswire

InnovAge to Announce Fourth Quarter and Fiscal 2025 Financial Results and Host Conference Call Tuesday, September 9, 2025
26/08/2025
DENVER, Aug. 26, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Prime Medicine to Participate in Upcoming Investor Conferences
26/08/2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
26/08/2025
Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company [...]
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
26/08/2025
WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
26/08/2025
TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
26/08/2025
SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive [...]
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
26/08/2025
Company advancing U.S. commercialization with FDA-approved ketamine and rare disorder NDA filings TORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: [...]
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
26/08/2025
Media Release COPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease [...]
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
26/08/2025
TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, [...]
Proxygen and EPFL Launch Strategic Collaboration to Advance AI-Driven Glue Discovery
26/08/2025
A new partnership brings together a validated discovery platform and cutting-edge computational innovation in targeted protein degradation VIENNA and LAUSANNE, Switzerland, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Proxygen , a [...]
Fulcrum Therapeutics to Present at Upcoming Investor Meetings
26/08/2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress
26/08/2025
Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home administration represents a potential [...]
Compass Therapeutics to Participate in Upcoming September Investor Events
26/08/2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat [...]
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
26/08/2025
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector ® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in [...]
Adagene to Participate in Two Investor Conferences in September
26/08/2025
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today [...]
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
26/08/2025
Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial data NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- [...]
Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
26/08/2025
Company to Advance Development of its Patented Device LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY ) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on [...]
PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
26/08/2025
SALT LAKE CITY, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PolarityBio , a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular [...]
Dr. Shai Efrati Honored With 2025 Ellis Island Medal of Honor
26/08/2025
Hyperbaric oxygen therapy pioneer and Aviv Clinics medical advisor honored for research and service to veterans and patients with stroke, PTSD, long COVID and more THE VILLAGES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- [...]

Pages